UBS AM
MRVI icon

UBS AM’s Maravai LifeSciences MRVI Stock Holding History

UBS AM’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-250,855
Closed -$554K – 2687
2025
Q1 		$554K Sell
250,855
-359
-0.1% -$1.42K ﹤0.01% 2481
2024
Q4 		$1.37M Buy
251,214
+45,454
+22% +$292K ﹤0.01% 2223
2024
Q3 		$1.71M Sell
205,760
-28,587
-12% -$247K ﹤0.01% 2127
2024
Q2 		$1.68M Buy
234,347
+37,284
+19% +$322K ﹤0.01% 2093
2024
Q1 		$1.71M Hold
197,063
– – ﹤0.01% 1767
2023
Q4 		$1.29M Sell
197,063
-433,332
-69% -$2.8M ﹤0.01% 1894
2023
Q3 		$6.3M Sell
630,395
-752,375
-54% -$8.26M ﹤0.01% 1124
2023
Q2 		$19.4M Hold
1,382,770
– – 0.01% 777
2023
Q1 		$19.4M Buy
+1,382,770
New +$19.9M 0.01% 777
2022
Q4 		– Sell
-2,152,901
Closed -$55M – 2682
2022
Q3 		$55M Sell
2,152,901
-312,997
-13% -$7.85M 0.03% 510
2022
Q2 		$70.1M Sell
2,465,898
-269,506
-10% -$8.54M 0.04% 470
2022
Q1 		$96.5M Sell
2,735,404
-1,780,696
-39% -$59.7M 0.04% 445
2021
Q4 		$189M Buy
4,516,100
+382,914
+9% +$15.5M 0.07% 287
2021
Q3 		$203M Buy
4,133,186
+594,447
+17% +$29M 0.08% 250
2021
Q2 		$148M Buy
3,538,739
+248,796
+8% +$9.64M 0.06% 329
2021
Q1 		$117M Sell
3,289,943
-473,069
-13% -$15.7M 0.05% 384
2020
Q4 		$106M Buy
+3,763,012
New +$105M 0.05% 391

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS AM's MRVI Position: Q2 2025 in Review

UBS AM sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 250,855 shares — an estimated $554K sold.

UBS AM first reported a position in MRVI in Q4 2020 and held it in 17 quarters. The position peaked at $203M in Q3 2021. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • UBS AM reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 250,855 Maravai LifeSciences shares in Q2 2025, an estimated $554K.
  • UBS AM first reported a position in Maravai LifeSciences in Q4 2020 and held it in 17 quarters.
  • UBS AM's Maravai LifeSciences position peaked at $203M in Q3 2021.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.